Table 1. UK clinical commissioning group or health authority structures in place relating to liver disease.

	Named person responsible for liver diseasen (%)	Pathway for assessing abnormal LFTsn (%)	Pathway for liverdisease more generallyn (%)	Processes in place tomonitor adoption and efficacy of pathwayn (%)	Monitoring of current local statistics relating to liver diseasen (%)
Englandn = 135	20 (15%)	49 (36%)	36 (27%)	21 (16%)	45 (33%)
Northern Irelandn = 5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Scotlandn = 12	6 (50%)	8 (67%)	5 (42%)	0 (0%)	6 (50%)
Walesn = 7	6 (86%)	7 (100%)	5 (71%)	1 (14%)	4 (57%)
UK totaln = 159	32 (20%)	64 (40%)	46 (29%)	22 (14%)	55 (35%)

LFTs = liver function tests. n = number of commissioning bodies.